Renal Cell Carcinoma

Robert J. Motzer, MD, shares his insights on the future of treatment for advanced renal cell carcinoma.

Dr Motzer discusses data from the CLEAR trial that were presented at ASCO 2021.

An expert explains the impact of the CLEAR trial on clinical practice and reviews NCCN guidelines for the management of advanced renal cell carcinoma.

Dr Robert J. Motzer introduces data from the phase 3 CLEAR trial, which investigated lenvatinib plus pembrolizumab or everolimus for the treatment of advanced renal cell carcinoma.

Robert J. Motzer, MD, gives a background on the current first-line therapy options for advanced renal cell carcinoma, including challenges and unmet needs.

Pembrolizumab plus lenvatinib demonstrated antitumor activity and a manageable safety profile in patients with metastatic renal cell carcinoma who have previously received immune checkpoint inhibitor therapy.

Viktor Grünwald, MD, PhD, reviews the efficacy findings of lenvatinib combined with pembrolizumab and sunitinib for the treatment of patients with advanced renal cell carcinoma.

An analysis of the phase 3 CheckMate 9ER trial revealed that cabozantinib exposure did not significantly correlate with progression-free survival but appeared to predict high rates 2 specific adverse events.

Updated findings for belzutifan showed that with further follow-up, the hypoxia-inducible factor-2 alpha inhibitor continues to show significant clinical activity in patients with Von-Hippel Lindau–associated renal cell carcinoma treated in the frontline setting. Updated results from the phase 2 study.

More the half of patients with metastatic renal cell carcinoma who received pembrolizumab in combination with cabozantinib had a response to the combination at the recommended phase 2 dose and tolerated treatment well.

Efficacy was improved with Lenvatinib plus pembrolizumab for patients with advanced renal cell carcinoma across evaluable International Metastatic RCC Database Consortium risk subgroups over sunitinib.

Few patients required subsequent anticancer therapies with the combination of lenvatinib (Lenvima) plus everolimus versus sunitinib for advanced renal cell carcinoma

Similar health-reatled quality of life outcomes and disease-related symptom scores were seen between the combination of lenvatinib plus pembrolizumab and sunitinib for the frontline treatment of metastatic renal cell carcinoma.

Median duration of response was doubled with tivozanib compared with sorafenib in patients with metastatic renal cell carcinoma.

Data from the phase 3 KEYNOTE-564 trial presented in a press briefing ahead of the 2021 ASCO Annual Meeting showed that adjuvant pembrolizuumab achieved significant disease-free survival improvement compared with placebo.

The CheckMate 9ER study compared nivolumab plus cabozantinib with sunitinib and found that as disease becomes less favorable by prognostic risk. Promise has now been shown for this population with the combination of lenvatinib and everolimus.

The American Urological Association updated its guidelines on Renal Masses and Localized Renal Cancer, expanding the use of genetic counseling and updating the use of active surveillance.

Sumanta Kumar Pal, MD, a medical oncologist at the City of Hope Cancer Center, discussed the SWOG 1500 trial, the potential of cabozantinib for the treatment of papillary RCC, and the future of RCC care in an interview with Targeted Oncology,

The FDA has granted priority review to 2 supplemental new drug applications for the combination use of pembrolizumab and lenvatinib.

During a virtual Targeted Oncology Case-Based Roundtable event, Moshe Ornstein, MD, MA, discussed the case of a 59-year-old patient with clear cell renal cell carcinoma.

In patients with advanced clear cell renal cell carcinoma, a phase 1b/2 umbrella platform study is evaluating the safety and efficacy of experimental combinations of investigational agents.

Thomas Hutson, DO, PharmD suggests the areas new research for non-clear cell renal cell carcinoma should explore.

As a class, immune checkpoint inhibitor-based regimens outshine select targeted therapies in overall survival in patients with metastatic non–clear cell renal cell carcinoma.

Although curing advanced RCC is an admirable goal, there are many treatment options available on the horizon that result in substantial improvements in long-term outcomes.

Recent updates to the National Comprehensive Cancer Network’s guidelines for renal cell carcinoma reflect quick integration of new agents and combination regimens to provide patients with RCC with more treatment options and the most up-to-date options.